Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study
Journal of Clinical Oncology · 10.06.2023 · 41 (17) · 3122-3134
DOI: 10.1200/jco.22.00074 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.06.2023. Verfasst von Lawson Eng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Ca…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Neoplasms. Die Arbeit wurde bisher 106-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
PURPOSE Antibiotic exposure before immune checkpoint inhibitor (ICI) treatment can negatively affect outcomes through alteration in the gut microbiome, but large-scale evaluations are lacking. We performed a population-level retrospective cohort study to evaluate the impact of antibiotic exposure before starting ICI on overall survival (OS). PATIENT AND METHODS Patients with cancer, age 65 years or older, who initiated treatment with ICIs between June 2012 and October 2018 in Ontario, Canada, were identified using systemic therapy administration data. The cohort was deterministically linked to other health care databases to obtain covariates and antibiotic prescription claim data at both 1 year and 60 days before ICI therapy. Multivariable Cox models evaluated the association between exposure and OS. RESULTS Among the 2,737 patients with cancer who received ICIs, 59% and 19% of patients received antibiotics 1 year and 60 days before ICI therapy, respectively. Median OS was 306 days. Any antibiotic exposure within 1 year before ICI was associated with worse OS (adjusted hazard ratio [aHR], 1.12; 95% CI, 1.12 to 1.23; P = .03). In antibiotic class analysis, exposure to fluoroquinolones within 1 year (aHR, 1.26; 95% CI, 1.13 to 1.40; P < .001) or 60 days before ICI (aHR, 1.20; 95% CI, 0.99 to 1.45; P = .06) was associated with worse OS, with a dose effect seen on the basis of total weeks of exposure over 1 year (aHR, 1.07 per week; 95% CI, 1.03 to 1.11; P < .001) and 60 days (aHR, 1.12 per week; 95% CI, 1.03 to 1.23; P = .01). CONCLUSION In this population-level study, exposure to antibiotics and specifically fluoroquinolones before ICI therapy was observed to be associated with worse OS among older adults with cancer. Interventions aimed at altering the gut microbiome to boost immunogenicity may help improve outcomes for patients receiving ICIs with prior antibiotic exposure. [Media: see text]
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
- Divison of Medical Oncology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Cancer Research Program, Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.
- Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
- Division of Hematology/Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
ORCID-Profile: Lawson Eng, Ning Liu, Melanie L Powis, Jeffrey M Peppercorn, Philippe L Bedard, Monika K Krzyzanowska
Zitieren
APA
Eng, L., Sutradhar, R., Niu, Y., Liu, N., Liu, Y., Kaliwal, Y., Powis, M. L., Liu, G., Peppercorn, J. M., Bedard, P. L., & Krzyzanowska, M. K. (2023). Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study. Journal of Clinical Oncology, 41(17), 3122-3134. https://doi.org/10.1200/jco.22.00074
Vancouver
Eng L, Sutradhar R, Niu Y, Liu N, Liu Y, Kaliwal Y, et al. Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study. Journal of Clinical Oncology. 2023;41(17):3122-3134. doi:10.1200/jco.22.00074
BibTeX
@article{Eng2023,
author = {Eng, Lawson and Sutradhar, Rinku and Niu, Yue and Liu, Ning and Liu, Ying and Kaliwal, Yosuf and Powis, Melanie L and Liu, Geoffrey and Peppercorn, Jeffrey M and Bedard, Philippe L and Krzyzanowska, Monika K},
title = {Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {17},
pages = {3122--3134},
doi = {10.1200/jco.22.00074}
}
EUVIMED